BIG new immunotherapy clinical trial just announced for MSS CRC! We'll actually be a lead solid tumor indication for one of the hottest immunotherapy targets: anti-CD47 (if you google it you'll see many hits). CD47 is a "don't eat me" signal sent to macrophages - the drug blocks it from doing this. An issue with anti-CD47 drugs is a small safety window but they are working to address that.
CD47 made a huge splash in the scientific world a few years ago with its preclinical data. People have been anxiously watching to see how it behaves in the clinic. The initial clinical focus was on blood cancers but they are now ready to start solid tumor testing - and MSS CRC is being chosen as an early test case!
Trial: NCT02953782
Drug name: Hu5F9-G4
Both KRAS WT and Mut
Combination with cetuximab
Locations: TX, MI, TN
Pretty loose inclusion/exclusion criteria
https://clinicaltrials.gov/ct2/show/NCT ... 016&rank=2
A link to a news story about the company "Forty Seven":
http://www.fiercebiotech.com/special-report/forty-seven
Preclinical papers:
http://www.pnas.org/content/109/17/6662.long
http://www.tandfonline.com/doi/full/10. ... 15.1011450
Cheers,
-DK